Accesswire 13-Oct-2017 9:00 AM
NEW YORK, NY / ACCESSWIRE / October 13, 2017 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on Endonovo Therapeutics, Inc. and has updated its target price to $0.20.
The note is available here: ENDV October 2017 Update.
Endonovo Therapeutics, Inc. (OTCQB: ENDV, "Endonovo") is a biotechnology company focused on developing non-invasive electroceuticals for the treatment of vascular diseases and inflammatory conditions in vital organs. Originally coined by GlaxoSmithKline (NYSE: GSK) in 2013, electroceuticals -also called bioelectronics - are medical devices that use electrical stimulation with an aim to treat a vast range of chronic diseases. Led by Chairman and CEO Alan Collier, Endonovo was founded in 2011 and is based in Los Angeles, CA. The company is a pre-clinical stage biotechnology firm seeking to advance a pipeline of electroceutical-based treatments for Non-Alcoholic Steatohepatitis (NASH), chronic kidney disease, and vascular diseases, including ischemic cardiomyopathy and limb ischemia.
ENDV led by differentiated Immunotronics Platform
Endonovo is developing two new platform technologies that utilize time-varying electromagnetic pulsetechnology. The company's lead Immunotronics Platform consists of non-invasive electroceuticals that utilize time-varying electromagnetic pulses to treat vascular diseases and inflammatory conditions in vital organs. The Immunotronics platform seeks to accomplish this by leveraging magnetically-induced electrical pulses to reduce inflammation and promote blood vessel cell growth. It is differentiated in the market due to the fact that it is a non-implantable device and also that it employs a time-varying electromagnetic field (TVEMF) approach, which the company believes has a slew rate and trapezoidal wave form, which is optimal for producing a cellular response and increasing stem cell growth. The company's second platform is its Cytotronics Platform, an application of time-varying electromagnetic pulse technology intended to enhance and expand cells and potentially for the development of advanced biologics.
Encouraging interim update for Myocardial Infarction
Endonovo has announced pre-clinical investigations of its electroceuticals from its Immunotronics Platform for a number of indications. On September 26, 2017, the company provided an encouraging interim update for its pre-clinical study investigating the use of the company's electroceuticals for the treatment and prevention of heart failure following Myocardial Infarction (a heart attack). In the announcement, Endonovo noted that its Immunotronics platform demonstrated improved cardiac function and less ventricular remodeling, as evaluated using echocardiography in infarcted animals treated with its non-invasive electroceutical two or three times per day for four weeks when compared to the control group. Management stated that it expects to provide final results including histology and cytokine data in coming weeks. We look forward to results from the study giving the significant potential of this market. Endonovo also announced that it has commenced a pre-clinical study of its electroceuticals on Critical Limb Ischemia, which is a serious form of peripheral arterial disease (PAD) characterized by severe blockage in the arteries of the lower extremities that reduces blood-flow. Other pre-clinical studies underway explore the use of ENDV's electroceuticals for Non-Alcoholic Steatohepatitis (NASH) and kidney disease.
Updating price target to $0.20
We are updating coverage of Endonovo for events since the last research note, which include changes to the company's share count and balance sheet, as well as the progression and status of its clinical pipeline. Endonovo is a speculative pre-clinical company in the biotechnology sector seeking to target a large market opportunity with its proprietary electroceutical products.
Please review important disclosures at www.seethruequity.com.
About Endonovo Therapeutics, Inc.
Endonovo Therapeutics, Inc. is a leading developer of bioelectronic-applications in cell therapies and non-invasive electroceuticals. Endonovo's Immunotronics platform is dedicated to treating patients with life-threatening inflammatory conditions in vital organs using proprietary non-invasive electroceutical devices. The Company's non-invasive platform is based on magnetically-induced electrical field pathways that target the disruption of inflammation and cell death.
The Company's Cytotronics platform harnesses the bulk electrical properties of cells and tissues, namely magnetically-induced electrical field pathways to expand and enhance the therapeutic potential of cell therapies and produce next-generation biologics.
Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion.
SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry's most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City.
For more information visit www.seethruequity.com.
Limited Time Offer:
Claim your free copy of income expert Bryan Perry's new report:
My Top Monthly Dividend Payer (8% Dividend Yield)
You'll also receive Bryan Perry's weekly e-letter, Dividend Investing Weekly, at no cost, along with other associated financial content and special offers.